At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 30 target
Drug / intervention
BL-M05D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06349811Phase 1RecruitingMonitorUpdated 12mo ago · Completion was 2mo agoSlow Enrollment
Monitor
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating BL-M05D1 for Locally Advanced or Metastatic Solid Tumors. Currently recruiting, targeting 30 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 1RecruitingOverdue
20252026
First PostedApr 2024
Enrollment StartApr 2024
Primary CompletionMay 2026
TodayJul 2026
First PostedApr 5, 2024
Enrollment StartApr 19, 2024
Primary CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.2 years ago
Interventions
BL-M05D1drug
Administration by intravenous infusion for a cycle of 3 weeks.